Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. TCR2 Therapeutics (TCRR) initiated with an Outperform at SVB Leerink, Wedbush, and BMO Capital, while being initiated with a Buy at Jefferies. 2. Barings BDC (BBDC) resumed with an Outperform at Wells Fargo. 3. Avedro (AVDR) initiated with an Overweight at JPMorgan while being initiated with an Outperform at SVB Leerink and Cowen. 4. Anchiano Therapeutics (ANCN) initiated with a Buy at Ladenburg and an Outperform at Oppenheimer. 5. CytomX Therapeutics (CTMX) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
Anchiano Therapeutics initiated with a Buy at Ladenburg. Ladenburg Thalmann analyst Matt Kaplan started Anchiano Therapeutics with a Buy rating and $20 price target. The analyst believes the company's lead product inodiftagene potentially represents a material advance for the treatment of non-muscle invasive bladder cancer and addresses an unmet medical need for commercially attractive markets. Inodiftagene could deliver U.S. sales of more than $340M by 2030, Kaplan tells investors in a research note.
Anchiano Therapeutics initiated with an Outperform at Oppenheimer. Oppenheimer analyst Leland Gershell initiated Anchiano Therapeutics with an Outperform rating and $16 price target. In a research note to investors, Gershell says Anchiano is committed to expanding treatment options for non-muscle invasive bladder cancer through its development of inodiftagene, a targeted biotherapeutic.